SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on May 31, 2002; DOI 10.1182/blood-2002-03-0675. This Article Full Text Full Text (PDF) All Versions of this Article: 2002-03-0675v1 100/7/2374    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Gratwohl, A. Articles by Urbano-Ispizua, A. Search for Related Content PubMed PubMed Citation Articles by Gratwohl, A. Articles by Urbano-Ispizua, A. Related Collections Transplantation Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 October 2002, Vol. 100, No. 7, pp. 2374-2386 CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Current trends in hematopoietic stem cell transplantation in Europe Alois Gratwohl, Helen Baldomero, Bruno Horisberger, Caroline Schmid, Jakob Passweg, and Alvaro Urbano-Ispizua for the Accreditation Committee of the European Group for Blood and Marrow Transplantation (EBMT) From the Division of Hematology, Department of Internal Medicine and Department of Research, Kantonsspital Basel, Switzerland; Research Institute for Management in Health Care (FMIG), St Gallen, Switzerland; and EBMT Secretariat, Hospital Clinic, Barcelona, Spain. Major changes have occurred in the transplantation of hematopoietic stem cells (HSCs) during the last decade. This report reveals the changes, reflects current status, and provides medium-term projections of HSC transplantation (HSCT) development in Europe. Data on 132 963 patients, 44 165 with allogeneic HSC transplant (33%) and 88 798 with an autologous HSC transplant (67%), collected prospectively from 619 centers by the European Group for Blood and Marrow Transplantation (EBMT) in 35 European countries between 1990 (4234 HSCTs) and 2000 (19 136 HSCTs) illustrate utilization of HSCT. HSCT increased in all European countries and for all indications. There were major differences depending on disease indication and donor type. Transplantation rates (numbers of HSCTs per 10 million inhabitants) varied from less than 1 for some rare indications to 37.7 ± 4.1 for acute myeloid leukemia in allogeneic HSCT or 95.5 ± 13.5 for non-Hodgkin lymphoma in autologous HSCT. There were indications with a steady, continuing increase and others with initial increase but subsequent decrease. Projections on medium-term development for each disease based on a weighted sensitivity analysis predict an ongoing increase in allogeneic HSCT except for chronic myeloid leukemia. In autologous HSCT they predict an increase for lymphoproliferative disorders, acute myeloid leukemia, myelodysplastic syndromes, and some solid tumors but a decrease for most solid tumors, acute lymphoid leukemia, and chronic myeloid leukemia. Transplantation rates can be predicted with reasonable sensitivity for most disease indications. Despite marked changes in the rapidly developing field of HSCT, this information on current use, trends, and midterm predictions forms a rational basis for patient counseling and health care planning. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: Y.-H. Loh, S. Agarwal, I.-H. Park, A. Urbach, H. Huo, G. C. Heffner, K. Kim, J. D. Miller, K. Ng, and G. Q. Daley Generation of induced pluripotent stem cells from human blood Blood, May 28, 2009; 113(22): 5476 - 5479. [Abstract] [Full Text] [PDF] J. de la Rubia, F. de Arriba, C. Arbona, M. J. Pascual, C. Zamora, A. Insunza, D. Martinez, C. Paniagua, M. A. Diaz, and M. A. Sanz Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry Haematologica, May 1, 2008; 93(5): 735 - 740. [Abstract] [Full Text] [PDF] C. Talarn, A. Urbano-Ispizua, R. Martino, J. A. Perez-Simon, M. Batlle, C. Herrera, M. Granell, A. Gaya, M. Torrebadell, F. Fernandez-Aviles, et al. Kinetics of recovery of dendritic cell subsets after reduced-intensity conditioning allogeneic stem cell transplantation and clinical outcome Haematologica, December 1, 2007; 92(12): 1655 - 1663. [Abstract] [Full Text] [PDF] A. Gratwohl, H. Baldomero, A. Schwendener, M. Gratwohl, J. Apperley, D. Niederwieser, K. Frauendorfer, and for the Joint Accreditation Committee of the Inter Predictability of hematopoietic stem cell transplantation rates Haematologica, December 1, 2007; 92(12): 1679 - 1686. [Abstract] [Full Text] [PDF] S. H. C. Baumeister, K. Holig, M. Bornhauser, M. Meurer, E. P. Rieber, and K. Schakel G-CSF mobilizes slanDCs (6-sulfo LacNAc+ dendritic cells) with a high proinflammatory capacity Blood, October 15, 2007; 110(8): 3078 - 3081. [Abstract] [Full Text] [PDF] F. Fernandez-Aviles, E. Carreras, A. Urbano-Ispizua, M. Rovira, C. Martinez, A. Gaya, M. Granell, L. Ramiro, C. Gallego, A. Hernando, et al. Case-Control Comparison of At-Home to Total Hospital Care for Autologous Stem-Cell Transplantation for Hematologic Malignancies J. Clin. Oncol., October 20, 2006; 24(30): 4855 - 4861. [Abstract] [Full Text] [PDF] E. S. Morris, K. P. A. MacDonald, and G. R. Hill Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL? Blood, May 1, 2006; 107(9): 3430 - 3435. [Abstract] [Full Text] [PDF] Stem Cell Trialists' Collaborative Group Allogeneic Peripheral Blood Stem-Cell Compared With Bone Marrow Transplantation in the Management of Hematologic Malignancies: An Individual Patient Data Meta-Analysis of Nine Randomized Trials J. Clin. Oncol., August 1, 2005; 23(22): 5074 - 5087. [Abstract] [Full Text] [PDF] K. Leibundgut, N. M.R. Schmitz, and A. Hirt Catalytic Activities of G1 Cyclin-Dependent Kinases and Phosphorylation of Retinoblastoma Protein in Mobilized Peripheral Blood CD34+ Hematopoietic Progenitor Cells Stem Cells, August 1, 2005; 23(7): 1002 - 1011. [Abstract] [Full Text] [PDF] A. Gratwohl, H. Baldomero, T. Demirer, G. Rosti, G. Dini, R. Ladenstein, and A. Urbano-Ispizua Hematopoetic stem cell transplantation for solid tumors in Europe Ann. Onc., April 1, 2004; 15(4): 653 - 660. [Abstract] [Full Text] [PDF] M. W. N. Deininger and B. J. Druker Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib Pharmacol. Rev., September 1, 2003; 55(3): 401 - 423. [Abstract] [Full Text] [PDF] M. H. Cottler-Fox, T. Lapidot, I. Petit, O. Kollet, J. F. DiPersio, D. Link, and S. Devine Stem Cell Mobilization Hematology, January 1, 2003; 2003(1): 419 - 437. [Abstract] [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020